Table of Contents Table of Contents
Previous Page  769 / 812 Next Page
Information
Show Menu
Previous Page 769 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

S765

Aims

– To analyze the proportion of patients treated with more

than one antipsychotic;

– to study clinical as sociodemographic variables associated with

types of prescription.

Methods

Retrospective descriptive study of treatment prescribed

to psychiatric inpatients treated in an acute care unit of Psychiatry

Service in a large teaching hospital during a period of 3 years. Con-

secutively admitted inpatients receiving concurrent antipsychotics

were compared with those treated with a single antipsychotic. Pre-

scription drug records at discharging were revised,

n

= 263.

Results

From the total sample, 61% received more than one

antipsychotic. The most common types of combinations were

atypical plus a typical antipsychotic followed by two atypi-

cal antipsychotics, being less frequent combination of three or

more antipsychotics. There were 19 different drug combinations.

Concurrent antipsychotics were most frequently prescribed in

schizophrenia and schizoaffective disorder. Patients with more

previous episodes of illness received more frequently concurrent

antipsychotics than patients with lownumber of previous episodes

of illness (

P

< 0.03). Patients with longer time of hospitalization, and

age between 30 and 50 years were treated more frequently with

several antipsychotics. Analysis with other variables is presented

in the study.

Conclusions

There is a significant difference in the strategies of

treatment with antipsychotics depending on diagnosis and num-

ber of previous episodes of illness. The concurrent use of multiple

antipsychotics in psychiatric inpatients appears to be a response to

treatment resistance and is frequent in schizophrenic patients.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2289

EV1305

Brief psychotherapy in eating

disorders

E. Garcia

1 ,

, M .

Leon

2 , F. P

olo

2 , R.

Martinez

3

1

Ciudad Real, Spain

2

Hospital General de Ciudad Real, UTCA, Ciudad Real, Spain

3

Hospital General de Ciudad Real, USMIJ, Ciudad Real, Spain

Corresponding author.

First time we began to work with eating disorders, we used to

hear the chronic course of the illness and the long-term treatment

that our patients would need. When you have a team trained in

brief psychotherapy, but not in this specific area, it sounds as just

the opposite you try to reach with your patients. National guide-

lines however are full of psycho-educational and cognitive-conduct

treatment’s models, without any other validated kind of treatment.

However, it was our experience that solution focused or prob-

lem focused therapy were also two clinical effective approaches

to many psychiatric problems. In fact, we had a mature consult,

in which as far as two thirds of patients had become, some way

chronic. Problem was, as far as we can imagine, if that was a dis-

ease’s effect or a lack of a deeper intervention, which were wider

than those classic. So, we classified our patients in resistant or not

resistant, and doing so we add brief therapy to the first group,

reevaluating every week each intervention and the course of the

illness. By doing so, we found that chronicity was, in same cases,

just the result of limited treatments. Here we have analysed some

chronic patientswith a bad course and the alternatives that let them

to recover.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2290

EV1306

Tech Connect: An innovative pilot

intervention to improve treatment

adherence for adolescents with mood

disorders

R. Gearing

1 ,

, K. Moore

2

, R. Guetta

3

1

University of Houston, GCSW, Houston, USA

2

Columbia University, Columbia, New York, USA

3

North Shore Child and Family Guidance Center, Child and Family,

New York, USA

Corresponding author.

Introduction

Over a third of adolescents terminate prematurely

from mental health treatment. A core underlying assumption of

most, if not all, evidence-based psychosocial interventions is that

patients will fully and actively engage in the treatment protocol.

Poor adherence remains a fundamental challenge in the treatment

of mood disorders in adolescents. Tech Connect is a proactive,

technology-assisted intervention of manualized between session

contacts and structural supports to increase adherence of ado-

lescents with depression who are at high risk of dropout from

treatment.

Objective

To test Tech Connect in a randomized controlled trial

(RCT) with depressed adolescents by:

– assessing feasibility;

– estimating preliminary intervention parameters;

– investigating adherence and mental health outcomes.

Methods

An RCT with depressed youths (13–17 years) who

were at high-risk for premature dropout were randomized to

Tech Connect (treatment condition) or standard community-based

care (control condition). Standardized measures assessed mental

health symptoms and outcomes, health beliefs, family involve-

ment, adherence, and therapeutic alliance.

Results

Results found significant differences between the num-

ber of treatment sessions attended by the adolescents assigned to

Tech Connect and those of the control group.

Conclusions

Tech Connect was designed to increase sessional

adherence in the early phase of treatment. All adolescents in the

treatment condition attended the first treatment session, with 90%

attending the targeted first 8 sessions. In comparison, only 40% of

adolescents in the control condition completed the first 8 sessions.

The Tech Connect Program is a novel, technologically driven inter-

vention designed to address this gap by improving engagement and

adherence to treatment.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2291

EV1307

Antidepressants and thyroid

hormones

S. Gómez Sánchez

1 ,

, L. Rodríguez Andrés

1

,

A. Rodríguez Campos

1

, C. Noval Canga

1

, A. Álvarez Astorga

1

,

A. San Román Uría

2

, G. Isidro García

1

, M. Hernández García

1

,

T. Ballesta Casanova

1

, L. Gallardo Borge

1

1

Hospital Clínico Universitario de Valladolid, Psiquiatría, Valladolid,

Spain

2

Complejo Asistencial de Zamora, Psiquiatría, Zamora, Spain

Corresponding author.

Introduction

Over the years, it has been shown that various

psychopharmaceuticals cause alterations on thyroid function. The

objective of this review is to summarize the most important thy-

roid side effects associated with them. Special attention is paid to

antidepressants, which are widely used and whose side effects are

not receiving the attention they deserve.

Clinical cases

This review presents three cases of patients who

were undergoing treatment with venlafaxine. Before the start of